Adrenal and Paraganglionic Tumors

TEAD1 signaling modulates adrenal chromaffin maturation

The paper identifies TEAD1 signaling as a critical regulator of chromaffin cell differentiation and function, and shows that SB699551 modulates this signaling to suppress pheochromocytoma cell proliferation.

TR-107, a novel mitochondrial ClpP agonist, induces robust antitumor activity against preclinical models of adrenocortical carcinoma

This study evaluates TR-107, a mitochondrial ClpP agonist, showing antitumor effects in ACC cell lines and organoids, with synergistic activity when combined with IGF-1R inhibitors.

Establishment of a patient-derived adrenocortical carcinoma 3D tumor construct platform for evaluation of therapeutic strategies

This paper develops patient-derived ACC tumor constructs to evaluate therapeutic strategies, showing they can test chemotherapies, targeted therapies, and immunotherapies.

Patient-derived organoids reveal hypoxia-driven plasticity and therapeutic vulnerabilities in pheochromocytomas and paragangliomas

This study uses patient-derived organoids to model pheochromocytomas and paragangliomas, revealing hypoxia-driven plasticity and therapeutic vulnerabilities, including responses to abemaciclib.

Transcriptional Subtypes on Immune Microenvironment and Predicting Postoperative Recurrence and Metastasis in Pheochromocytoma and Paraganglioma

The paper identifies three transcriptional subtypes of PPGLs based on immune and genomic features, linking them to prognosis and potential therapeutic targets.

A genetic signature predicts aggressive paraganglioma sensitivity to dual PI3K-CDK4/6 inhibition therapy

Single Nuclei Sequencing Reveals Replication Stress in Adrenocortical Carcinoma

The paper uses single nuclei RNA sequencing to identify replication stress and DNA damage response in adrenocortical carcinoma, suggesting ATR as a potential therapeutic target.

An integrated bioinformatics approach to identify candidate biomarkers and the evaluation of drugs for pheochromocytoma

This study identifies potential biomarkers and evaluates Lenvatinib as a drug target for pheochromocytoma using bioinformatics analysis of gene expression and molecular docking.